KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Royalty Pharma (RPRX) over the last 6 years, with Q4 2025 value amounting to $110.8 million.

  • Royalty Pharma's Accumulated Expenses rose 1300.81% to $110.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $110.8 million, marking a year-over-year increase of 1300.81%. This contributed to the annual value of $110.8 million for FY2025, which is 1300.81% up from last year.
  • According to the latest figures from Q4 2025, Royalty Pharma's Accumulated Expenses is $110.8 million, which was up 1300.81% from $29.0 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Accumulated Expenses ranged from a high of $110.8 million in Q4 2025 and a low of $10.3 million during Q1 2021
  • Its 5-year average for Accumulated Expenses is $42.2 million, with a median of $40.7 million in 2021.
  • Per our database at Business Quant, Royalty Pharma's Accumulated Expenses skyrocketed by 20497.82% in 2024 and then tumbled by 2438.82% in 2025.
  • Royalty Pharma's Accumulated Expenses (Quarter) stood at $57.7 million in 2021, then fell by 6.13% to $54.2 million in 2022, then fell by 4.58% to $51.7 million in 2023, then skyrocketed by 89.74% to $98.1 million in 2024, then rose by 13.01% to $110.8 million in 2025.
  • Its Accumulated Expenses was $110.8 million in Q4 2025, compared to $29.0 million in Q3 2025 and $85.6 million in Q2 2025.